Tremor in demyelinating neuropathy, a study on the prevalence, etiology and characteristics of tremor in demyelinating neuropathy - Tremor in demyelinating neuropathy

Academisch Medisch Centrum0 个研究点目标入组 260 人开始时间: 待定最近更新: 2024年4月15日

适应症

试验速览

暂无简介。

•Patients with demyelinating neuropathy with and without tremor
•For the diagnosis CIDP we will use the EFNS/PNS criteria for the diagnosis of
•CIDP. In addition we will include patients fulfilling the clinical criteria and
•at least two supportive criteria (24).
•2) IgM paraproteinemic neuropathy
•Patients with chronic distal polyneuropathy with either axonal or demyelinating
•characteristics and presence of monoclonal IgM antibodies (24).
•3) CMT-1A and CMT-1B
•Patients with uniform demyelinating polyneuropathy, genetically confirmed in
•patient or in a first degree relative.
•Patients with axonal neuropathy with and without tremor
•- EMG confirmed axonal polyneuropathy according to EMG examination in Amsterdam
•UMC or patients clinically diagnosed with a chronic axonal polyneuropathy
•during an outpatient clinic visit at the AMC, without an EMG examination. These
•patients will be included by searching electronic health records in the time
•frame of January 1st until December 31st 2017;
•- the etiology of the neuropathy is either diabetes mellitus, chronic
•idiopathic axonal polyneuropathy (CIAP) or medication induced (provided the
•causative drug cannot induce tremor) according to the last diagnosis registered
•and is not associated with demyelinating disorders;
•- neuropathy with a chronic course (symptoms for over 3 months).
•Additional inclusion criteria that apply to all groups above:
•- age >=18 years
•- informed consent

发起方